MarginsXMarginsX
Home › Markets › Health Care › ZYBT

Zhengye Biotechnology Holding Limited (ZYBT)

ZYBT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.43
-4.67% on the day
Market cap
$67.8M
Micro cap
Revenue · 2025
$16.6M
-34.8% on 2024
Net income · 2025
-$10.0M
-60.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1975641/000121390026048584/0001213900-26-048584-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerZYBT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryChina
IPO year2025
SEC CIK0001975641
SEC industry codePharmaceutical Preparations
Incorporated inChina

Financials · 2025

LineValue
Revenue$16.6M
Net income-$10.0M
Operating income-$10.1M
Net margin-60.0%
Operating margin-60.6%
Revenue growth-34.8%
Cash$7.2M
Total assets$62.4M
P/E (computed)Net income was not positive
P/S (computed)4.1×

Warning signs

Cash runway
Cash-flow positive
$7.2M cash at December 31, 2025
Share count, 1 year
+3.8%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed April 28, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-28
Cash and burn$7.2M cash; operating cash flow $478K a quarter.Report 2025-12-31
Shares outstanding47,391,376 (2025-12-31); 45,666,376 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWWC, P.C., San Mateo, California, United StatesPCAOB Form AP 2026-05-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$16.6M-$10.0M$1.9M$7.2M$10.7M$16.6M20-F 2026-04-28
FY 2024
2024-12-31
$25.5M$1.6M$5.6M$2.5M$11.8M$25.5M20-F 2025-07-03

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42025-01-07
Latest annual report
ANNUAL REPORT
20-F2026-04-28
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-12

Source: SEC EDGAR submissions feed, 62 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week0.0%
1 month+1.4%
3 months-2.0%
Year to date+30.4%
1 year-30.2%
From 52-week high-81.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TENXTenax Therapeutics Inc.$1.48-8.64%$67.4M
GOSSGossamer Bio Inc.$10.98+0.09%$67.2M
MNOVMedicinova Inc$1.34-3.94%$68.7M
CRBPCorbus Pharmaceuticals Holdings Inc.$3.38-0.44%$69.5M
COYACoya Therapeutics Inc.$3.00-4.15%$70.4M
VTVTvTv Therapeutics Inc.$17.69-10.16%$71.0M
TLSATiziana Life Sciences Ltd. Common Shares$0.5762+1.11%$73.3M
ACRVAcrivon Therapeutics Inc.$1.46+0.69%$62.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier